Loading…
The hidden architects of glioblastoma multiforme: Glioma stem cells
Glioblastoma multiforme (GBM), a WHO grade IV diffuse glioma, is a highly aggressive brain tumor with a median survival of less than a year. Characterized by robust proliferation and invasion, recent studies spotlight glioma stem cells (GSCs) within GBM tumors, pivotal in tumor development, progress...
Saved in:
Published in: | MedComm - Oncology 2024-03, Vol.3 (1), p.n/a |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Glioblastoma multiforme (GBM), a WHO grade IV diffuse glioma, is a highly aggressive brain tumor with a median survival of less than a year. Characterized by robust proliferation and invasion, recent studies spotlight glioma stem cells (GSCs) within GBM tumors, pivotal in tumor development, progression, and treatment resistance. This review aims to shed light on the critical role of GSCs in the initiation and progression of GBM, emphasizing their contribution to tumor development and resistance to existing treatments. Unlike normal stem cells, GSCs play a pivotal role in GBM pathogenesis. The review delves into the unique characteristics of GSCs, marked by heightened metabolic activities and distinct epigenetic and transcriptional programming. Recognizing the significance of GSCs in recent years, the review examines how their presence amplifies the lethal nature of GBM. The review also critically evaluates recent advancements in glioma and GBM diagnostic methods and treatment therapies, which also include targeting GSCs. Providing a concise yet comprehensive overview, the review contributes insights into GBM's intricate dynamics, offering potential directions for future research and therapeutic strategies.
Glioma stem cells (GSCs) play a central role in the dynamics of glioblastoma multiforme (GBM). They initiate tumor formation and drive heterogeneity through self‐renewal. As the cancer progresses, GSCs infiltrate the brain tissue and help resist therapy, thereby leading to recurrence. Targeting GSCs holds promise in disrupting GBM progression, given their pivotal role in initiation, progression, and the challenges of therapy. |
---|---|
ISSN: | 2769-6448 2769-6448 |
DOI: | 10.1002/mog2.66 |